FTP 002 /FTP 501
Alternative Names: FTP-002/FTP-501Latest Information Update: 26 Sep 2025
At a glance
- Originator Fastox Pharma
- Class Bacterial toxins; Skin disorder therapies
- Mechanism of Action Muscle modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glabellar lines
Most Recent Events
- 26 Nov 2024 Phase-I/II clinical trials in Glabellar lines (In volunteers) in Germany (IM) (CTIS2023-507249-27-00)